PLYX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

7.389

Open

3.290

VWAP

5.55

Vol

25.03M

Mkt Cap

282.64M

Low

3.290

Amount

138.93M

EV/EBITDA(TTM)

Total Shares

47.34M

276.89M

EV/OCF(TTM)

P/S(TTM)

Events Timeline

(ET)

2026-02-17

08:40:00

Polaryx Therapeutics Selects CRO for Soteria Clinical Trial

2026-02-10 (ET)

2026-02-10

08:40:00

Polaryx Therapeutics Presents New Data for PLX-200 at WORLDSymposium

2026-02-06 (ET)

2026-02-06

10:20:00

Polaryx Therapeutics Trading Halted

2026-02-05 (ET)

2026-02-05

15:30:00

Polaryx Therapeutics Trading Halted

2026-02-05

08:50:00

Polaryx Therapeutics Appoints New Board Members

News

8.5

07:10 AMstocktwits

PinnedPolaryx Therapeutics Shares Surge Post-Listing

8.5

02-27Newsfilter

Polaryx's Commitment to Rare Disease Treatment

8.5

02-18Benzinga

Polaryx Therapeutics Stock Volatility After Major Clinical Announcement

4.5

02-18Benzinga

U.S. Stocks Rise in Morning Trading, Dow Up Approximately 100 Points

8.5

02-17Benzinga

Polaryx Therapeutics Advances Clinical Programs Significantly

8.5

02-17Newsfilter

Polaryx Selects CRO to Advance PLX-200 Clinical Trial for Rare Disorders

0 Analyst Rating

Wall Street analysts forecast PLYX stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Maxim

NULL -> Buy

initiated

$10

AI Analysis

2026-02-27

Reason

Maxim

Price Target

$10

AI Analysis

2026-02-27

initiated

NULL -> Buy

Reason

Maxim initiated coverage of Polaryx with a Buy rating and $10 price target.

Maxim

initiated

$10

2026-02-27

Reason

Maxim

Price Target

$10

2026-02-27

initiated

Reason

As previously reported, Maxim initiated coverage of Polaryx with a Buy rating and $10 price target. The company is aiming to rapidly emerge in the high-value rare disease category through development of PLX-200, a repurposed FDA-approved lipid-lowering drug - LSD - for treatment of lysosomal storage disorders, the analyst tells investors in a research note. The firm views PLX-200 as differentiated given its patient-friendly oral formulation and potential to address a broad spectrum of LSDs by targeting shared disease pathways rather than targeting single gene/enzyme defects, Maxim adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PLYX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Polaryx Therapeutics, Inc (PLYX.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Polaryx Therapeutics, Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding PLYX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Polaryx Therapeutics, Inc (PLYX) stock price today?

The current price of PLYX is 5.97 USD — it has increased 69.6

What is Polaryx Therapeutics, Inc (PLYX)'s business?

What is the price predicton of PLYX Stock?

Wall Street analysts forecast PLYX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLYX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Polaryx Therapeutics, Inc (PLYX)'s revenue for the last quarter?

Polaryx Therapeutics, Inc revenue for the last quarter amounts to -974.00K USD, increased 26.33

What is Polaryx Therapeutics, Inc (PLYX)'s earnings per share (EPS) for the last quarter?

Polaryx Therapeutics, Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Polaryx Therapeutics, Inc (PLYX). have?

Polaryx Therapeutics, Inc (PLYX) has 0 emplpoyees as of March 11 2026.

What is Polaryx Therapeutics, Inc (PLYX) market cap?

Today PLYX has the market capitalization of 282.64M USD.

PLYX Overview

PLYX Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding PLYX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Polaryx Therapeutics, Inc (PLYX) stock price today?

What is Polaryx Therapeutics, Inc (PLYX)'s business?

What is the price predicton of PLYX Stock?

What is Polaryx Therapeutics, Inc (PLYX)'s revenue for the last quarter?

What is Polaryx Therapeutics, Inc (PLYX)'s earnings per share (EPS) for the last quarter?

How many employees does Polaryx Therapeutics, Inc (PLYX). have?

What is Polaryx Therapeutics, Inc (PLYX) market cap?